Specify a stock or a cryptocurrency in the search bar to get a summary
Atossa Genetics Inc
ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Address: 107 Spring Street, Seattle, WA, United States, 98104
Analytics
WallStreet Target Price
4.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ATOS
Dividend Analytics ATOS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATOS
Stock Valuation ATOS
Financials ATOS
Results | 2019 | Dynamics |